Neostem (NBS) 3.78 $NBS
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
NeoStem to Present at BIO CEO & Investor Conference and at Sachs Associates Cancer Bio Partnering & Investment Forum
GlobeNewswire - Thu Feb 05, 4:17PM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today that the Company's management will present at the BIO CEO & Investor Conference on February 9 and at Sachs Associates Cancer Bio Partnering & Investment Forum on February 23.
NBS: 3.78 (+0.14)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
NeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD, to Its Board of Directors
GlobeNewswire - Thu Jan 22, 7:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the addition of Peter G. Traber, MD, to its Board of Directors.
NBS: 3.78 (+0.14), GALT: 3.84 (+0.16), GSK: 47.94 (+1.99)
NeoStem Receives Drug Manufacture License for Irvine Facility
GlobeNewswire - Tue Jan 20, 6:33AM CST
NeoStem, Inc. (Nasdaq:NBS) a leader in the development and manufacturing of cell therapy products and regenerative medicine, announced today that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T (also known as NBS20) and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the Company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.
NBS: 3.78 (+0.14)
NeoStem and Invetech Announce Agreement to Develop Closed Processing System for Cell Therapy Manufacturing
GlobeNewswire - Mon Jan 12, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, and Invetech Pty Ltd ("Invetech" , a global leader in instrument development, custom automation and contract manufacturing, today announced an agreement for the development of a new closed processing system (the "System" for cell therapy manufacturing. Under the agreement, Invetech will provide system design and engineering development and NeoStem will develop applications for performing closed cell processing manipulations such as separation. The agreement envisions NeoStem as the commercial supplier of the System which would constitute its first branded entry into the cell therapy tools market.
NBS: 3.78 (+0.14)
Neostem Up 7.9%, Shares Break Through Resistance (NBS)
Comtex SmarTrend(R) - Fri Jan 09, 12:41PM CST
Neostem (AMEX:NBS) is one of today's best performing low-priced stocks, up 7.9% to $3.96 on 1.0x average daily volume. Neostem has traded 360,000 shares thus far today, vs. average volume of 356,000 shares per day. The stock has outperformed the Dow (7.9% to the Dow's -0.9%) and outperformed the S&P 500 (7.9% to the S&P's -0.8%) during today's trading.
NBS: 3.78 (+0.14)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Neostem, Inc. Regarding Possible Breaches of Fiduciary Duty - NBS
PR Newswire - Thu Jan 08, 12:51PM CST
Levi & Korsinsky, LLP is investigating Neostem, Inc. (NasdaqCM: NBS) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
NBS: 3.78 (+0.14)
NeoStem, Inc. "Strengthening NeoStem's Executive Management with Two Significant Hires"
ACCESSWIRE - Wed Jan 07, 7:45AM CST
New York, NY / ACCESSWIRE / January 7, 2015 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman, Dr. Robin L. Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.78 (+0.14)
NeoStem Strengthens Executive Management With Appointments of David J. Mazzo, PhD as Chief Executive Officer and Robert S. Vaters as President and Chief Financial Officer and Elects Robin Smith, MD to Executive Chair of the Board
GlobeNewswire - Mon Jan 05, 8:01AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the appointments of David J. Mazzo, PhD as Chief Executive Officer (CEO) and Robert S. Vaters as President and Chief Financial Officer (CFO). Both Dr. Mazzo and Mr. Vaters will also serve as directors of the corporation. Simultaneously, Robin Smith, MD has been elevated to the position of Executive Chair of the Board of Directors.
NBS: 3.78 (+0.14)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
PCT, a NeoStem Company, Presented Lovo(R) Cell Processing System Data at IBC Life Sciences' Commercialization of Cell, Gene & Immunotherapies Conference
GlobeNewswire - Mon Dec 15, 6:39AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, and Progenitor Cell Therapy, LLC ("PCT" , a NeoStem company and a leading contract development and manufacturing organization in the cellular therapy industry, announced that Dr. Ian Gaudet, Senior Engineer with PCT's Engineering and Innovation Center, presented results of PCT's most recent study to generate data on the performance of the Lovo Cell Processing System.
NBS: 3.78 (+0.14)
NeoStem's Subsidiary, Progenitor Cell Therapy, Earns AABB Re-Accreditation for Its Allendale, NJ Manufacturing Facility
GlobeNewswire - Mon Dec 08, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel cell based therapeutics, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , announced today that PCT has been awarded re-accreditation by AABB (formerly known as the American Association of Blood Banks) in the category of "Cell Therapy Activity: Cord Blood - Processing, Storage and Distribution" for its Allendale, NJ facility. Accreditation follows an intensive on-site assessment by specially trained AABB assessors and establishes that the level of technical and administrative performance within the facility meets or exceeds the standards set by AABB.
NBS: 3.78 (+0.14)
Insider Trading Alert - UGI, NBS And MACK Traded By Insiders
at The Street - Fri Dec 05, 10:15AM CST
Stocks with insider trader activity include UGI, NBS and MACK
MACK: 10.22 (+0.40), UGI: 34.51 (-0.20), NBS: 3.78 (+0.14)
NeoStem, Inc. - "Initial Trial Results of PreSERVE AMI: The Meaningful Clinical Relevance of the Data"
ACCESSWIRE - Tue Dec 02, 7:33AM CST
New York, NY / ACCESSWIRE / December 2, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Robin L. Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.78 (+0.14)
NeoStem and PCT, A NeoStem Company, to Present at Multiple December Conferences
GlobeNewswire - Mon Dec 01, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a biopharmaceutical company developing novel cell based therapies, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , will present at multiple upcoming conferences in December.
NBS: 3.78 (+0.14)
NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014
GlobeNewswire - Wed Nov 26, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 to 5:30 PM EST.
NBS: 3.78 (+0.14)
NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine
GlobeNewswire - Tue Nov 25, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) announced today that Dr. Robert Preti, the Company's Chief Scientific Officer and President of its subsidiary, Progenitor Cell Therapy ("PCT" , has been elected Vice Chairman of the Alliance for Regenerative Medicine (ARM), an international organization representing the regenerative medicine and advanced therapies community. Dr. Preti will serve in this role effective January 1, 2015.
NBS: 3.78 (+0.14)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
NeoStem to Present at BIO CEO & Investor Conference and at Sachs Associates Cancer Bio Partnering & Investment Forum
GlobeNewswire - Thu Feb 05, 4:17PM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today that the Company's management will present at the BIO CEO & Investor Conference on February 9 and at Sachs Associates Cancer Bio Partnering & Investment Forum on February 23. NBS: 3.78 (+0.14)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)
NeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD, to Its Board of Directors
GlobeNewswire - Thu Jan 22, 7:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the addition of Peter G. Traber, MD, to its Board of Directors.
NBS: 3.78 (+0.14), GALT: 3.84 (+0.16), GSK: 47.94 (+1.99)
NeoStem Receives Drug Manufacture License for Irvine Facility
GlobeNewswire - Tue Jan 20, 6:33AM CST
NeoStem, Inc. (Nasdaq:NBS) a leader in the development and manufacturing of cell therapy products and regenerative medicine, announced today that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T (also known as NBS20) and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the Company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.
NBS: 3.78 (+0.14)
NeoStem and Invetech Announce Agreement to Develop Closed Processing System for Cell Therapy Manufacturing
GlobeNewswire - Mon Jan 12, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, and Invetech Pty Ltd ("Invetech"
, a global leader in instrument development, custom automation and contract manufacturing, today announced an agreement for the development of a new closed processing system (the "System" for cell therapy manufacturing. Under the agreement, Invetech will provide system design and engineering development and NeoStem will develop applications for performing closed cell processing manipulations such as separation. The agreement envisions NeoStem as the commercial supplier of the System which would constitute its first branded entry into the cell therapy tools market. NBS: 3.78 (+0.14)
Neostem Up 7.9%, Shares Break Through Resistance (NBS)
Comtex SmarTrend(R) - Fri Jan 09, 12:41PM CST
Neostem (AMEX:NBS) is one of today's best performing low-priced stocks, up 7.9% to $3.96 on 1.0x average daily volume. Neostem has traded 360,000 shares thus far today, vs. average volume of 356,000 shares per day. The stock has outperformed the Dow (7.9% to the Dow's -0.9%) and outperformed the S&P 500 (7.9% to the S&P's -0.8%) during today's trading.
NBS: 3.78 (+0.14)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Neostem, Inc. Regarding Possible Breaches of Fiduciary Duty - NBS
PR Newswire - Thu Jan 08, 12:51PM CST
Levi & Korsinsky, LLP is investigating Neostem, Inc. (NasdaqCM: NBS) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
NBS: 3.78 (+0.14)
NeoStem, Inc. "Strengthening NeoStem's Executive Management with Two Significant Hires"
ACCESSWIRE - Wed Jan 07, 7:45AM CST
New York, NY / ACCESSWIRE / January 7, 2015 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman, Dr. Robin L. Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.78 (+0.14)
NeoStem Strengthens Executive Management With Appointments of David J. Mazzo, PhD as Chief Executive Officer and Robert S. Vaters as President and Chief Financial Officer and Elects Robin Smith, MD to Executive Chair of the Board
GlobeNewswire - Mon Jan 05, 8:01AM CST
NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, today announced the appointments of David J. Mazzo, PhD as Chief Executive Officer (CEO) and Robert S. Vaters as President and Chief Financial Officer (CFO). Both Dr. Mazzo and Mr. Vaters will also serve as directors of the corporation. Simultaneously, Robin Smith, MD has been elevated to the position of Executive Chair of the Board of Directors.
NBS: 3.78 (+0.14)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
PCT, a NeoStem Company, Presented Lovo(R) Cell Processing System Data at IBC Life Sciences' Commercialization of Cell, Gene & Immunotherapies Conference
GlobeNewswire - Mon Dec 15, 6:39AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, and Progenitor Cell Therapy, LLC ("PCT"
, a NeoStem company and a leading contract development and manufacturing organization in the cellular therapy industry, announced that Dr. Ian Gaudet, Senior Engineer with PCT's Engineering and Innovation Center, presented results of PCT's most recent study to generate data on the performance of the Lovo Cell Processing System. NBS: 3.78 (+0.14)
NeoStem's Subsidiary, Progenitor Cell Therapy, Earns AABB Re-Accreditation for Its Allendale, NJ Manufacturing Facility
GlobeNewswire - Mon Dec 08, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel cell based therapeutics, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , announced today that PCT has been awarded re-accreditation by AABB (formerly known as the American Association of Blood Banks) in the category of "Cell Therapy Activity: Cord Blood - Processing, Storage and Distribution" for its Allendale, NJ facility. Accreditation follows an intensive on-site assessment by specially trained AABB assessors and establishes that the level of technical and administrative performance within the facility meets or exceeds the standards set by AABB. NBS: 3.78 (+0.14)
Insider Trading Alert - UGI, NBS And MACK Traded By Insiders
at The Street - Fri Dec 05, 10:15AM CST
Stocks with insider trader activity include UGI, NBS and MACK
MACK: 10.22 (+0.40), UGI: 34.51 (-0.20), NBS: 3.78 (+0.14)
NeoStem, Inc. - "Initial Trial Results of PreSERVE AMI: The Meaningful Clinical Relevance of the Data"
ACCESSWIRE - Tue Dec 02, 7:33AM CST
New York, NY / ACCESSWIRE / December 2, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Robin L. Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.78 (+0.14)
NeoStem and PCT, A NeoStem Company, to Present at Multiple December Conferences
GlobeNewswire - Mon Dec 01, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a biopharmaceutical company developing novel cell based therapies, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , will present at multiple upcoming conferences in December. NBS: 3.78 (+0.14)
NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014
GlobeNewswire - Wed Nov 26, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 to 5:30 PM EST.
NBS: 3.78 (+0.14)
NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine
GlobeNewswire - Tue Nov 25, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) announced today that Dr. Robert Preti, the Company's Chief Scientific Officer and President of its subsidiary, Progenitor Cell Therapy ("PCT"
, has been elected Vice Chairman of the Alliance for Regenerative Medicine (ARM), an international organization representing the regenerative medicine and advanced therapies community. Dr. Preti will serve in this role effective January 1, 2015. NBS: 3.78 (+0.14)
